Subclinical Macular Edema as a Predictor of Progression to Central-Involved Macular Edema in type 2 diabetes

Subclinical Macular Edema as a Predictor of Progression to Central-Involved Macular Edema in type 2 diabetes

Subclinical Macular Edema as a Predictor of Progression to Central-Involved Macular Edema in type 2 diabetes

Lobo C., Pires I., Alves D., Pappuru R., Ribeiro L., Cunha-Vaz J.

Ophthalmic Res 2018;60:18–22 (DOI:10.1159/000486792)

2018

Effects of topically administered neuroprotective drugs in early stages of diabetic retinopathy. Results of the EUROCONDOR clinical trial

Effects of topically administered neuroprotective drugs in early stages of diabetic retinopathy. Results of the EUROCONDOR clinical trial

Effects of topically administered neuroprotective drugs in early stages of diabetic retinopathy. Results of the EUROCONDOR clinical trial

Rafael Simó*, Cristina Hernández, Massimo Porta, Francesco Bandello, Jakob Grauslund, Simon P. Harding, Stephen J. Aldington, Catherine Egan, Ulrik Frydkjaer-Olsen, José García-Arumí, Jonathan Gibson, Gabriele E. Lang, Rosangela Lattanzio, Pascale Massin, Edoardo Midena, Berta Ponsati, Luísa Ribeiro, Peter Scanlon, Miguel Ângelo Costa, and José Cunha-Vaz*, for the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR)

Diabetes. 2018 Nov 2. pii: db180682. doi: 10.2337/db18-0682.

2018

The Decreasing Prevalence of Nonrefractive Visual Impairment in Older Europeans: A Meta-analysis of Published and Unpublished Data.

The Decreasing Prevalence of Nonrefractive Visual Impairment in Older Europeans: A Meta-analysis of Published and Unpublished Data.

The Decreasing Prevalence of Nonrefractive Visual Impairment in Older Europeans: A Meta-analysis of Published and Unpublished Data.

Cécile Delcourt, Mélanie Le Goff, Therese von Hanno, Alireza Mirshahi, Anthony P. Khawaja, Virginie J.M. Verhoeven, Ruth E. Hogg, Eleftherios Anastosopoulos, Maria Luz Cachulo, René Hohn, Christian Wolfram, Alain Bron, Stefania Miotto, Isabelle Carrière, Johanna Colijn, Gabrielle H.S. Buitendijk, Jennifer Evans, Dorothea Nitsch, Panayiota Founti, Jennifer L.Y. Yip, Norbert Pfeiffer, Catherine Creuzot-Garcher, Rufino Silva, Stefano Piermarocchi, Fotis Topouzis, Geir Bertelsen, Paul J. Foster, Astrid Fletcher, Caroline C.W. Klaver, Jean-François Korobelnik, for the European Eye Epidemiology Consortium.

Ophthalmology 2018, Mar 13. pii: S0161-6420(17)32612-X. Doi: 10.1016/j.ophth. 2018.02.005 [Epub ahead of print]

2018

MACUSTAR: Development and clinical validation of functional, structural and patient-reported endpoints in intermediate age-related macular degeneration

MACUSTAR: Development and clinical validation of functional, structural and patient-reported endpoints in intermediate age-related macular degeneration

MACUSTAR: Development and clinical validation of functional, structural and patient-reported endpoints in intermediate age-related macular degeneration

Robert P. Finger, Steffen SchmitzValckenberg, Matthias Schmid, Gary S. Rubin, Hannah Dunbar, Adnan Tufail, David P. Crabb, Alison Binns, Clara I. Sánchez, Philippe Margaron, Guillaume Normand, Mary Durbin, Ulrich Luhmann, Parisa Zamiri, José Cunha-Vaz, Friedrich Asmus, Frank G. Holz, Jan Henrik Terheyden

Ophthalmologica. 2019;241(2):61-72. doi: 10.1159/000491402. Epub 2018 Aug 28. Review.

2019

Systemic and Ocular Determinants of Peripapillary Retinal Nerve Fiber Layer Thickness Measurements in the European Eye Epidemiology (E3) Population.

Systemic and Ocular Determinants of Peripapillary Retinal Nerve Fiber Layer Thickness Measurements in the European Eye Epidemiology (E3) Population.

Systemic and Ocular Determinants of Peripapillary Retinal Nerve Fiber Layer Thickness Measurements in the European Eye Epidemiology (E3) Population.

Mauschitz M, Bonnemaijer P, Diers K, Rauscher F, Elze T, Engel C, Loeffler M, Colijn J, Ikram MA, Vingerling J, Williams K, Hammond C, Creuzot-Garcher C, Bron A, MD, Silva R, Nunes S, Delcourt C, Cougnard-Grégoire A, Holz F, Klaver C, Breteler M, Finger R, on behalf of the European Eye Epidemiology(E3) Consortium.

Ophthalmology. 2018 Apr 28. pii: S0161-6420(17)33477-2. doi: 10.1016/j.ophtha.2018.03.026

2018

Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries

Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries

Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries

Usha Chakravarthy, Simon R Taylor, Frank H Johannes Koch, João Paulo Castro de Sousa, Clare Bailey

Br J Ophthalmol 2018;0:1-doi.org/10.1136/bjophthalmol-2018-312284

2018

Methodologic assessment of the systematic reviews of ophthalmic adverse drug reactions published in Ophthalmology journals: a systematic review

Methodologic assessment of the systematic reviews of ophthalmic adverse drug reactions published in Ophthalmology journals: a systematic review

Methodologic assessment of the systematic reviews of ophthalmic adverse drug reactions published in Ophthalmology journals: a systematic review

Penedones A, Batel-Marques F

PURPOSE:

This systematic review aims to characterize and review the methodology of the systematic reviews reporting ophthalmic adverse drug reactions.

METHODS:

This systematic review followed the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-analyses guide. MEDLINE and EMBASE databases were searched, by all Ophthalmology journals. All systematic reviews reporting ophthalmic adverse drug reactions in the last decade were included. Data on methodology were extracted. Methodological quality was assessed through A MeaSurement Tool to Assess systematic Reviews 2 scale. Descriptive analysis was performed.

RESULTS:

Twenty-one systematic reviews were identified. Almost 60% of the systematic reviews reported non-ophthalmic drugs. Nine (43%) systematic reviews did not follow any recommendation. A search filter was not applied in 48% systematic reviews. Observational data was the source of information most included. The methodological quality was assessed in 57% systematic reviews. A meta-analysis was performed in 57% systematic reviews. The protocol’s elaboration, the explanation of the sources of information and the list of excluded articles were the domains less performed in the systematic reviews.

CONCLUSION:

The systematic reviews reporting ophthalmic adverse drug reactions diverged in some methodological aspects. Such an issue deserves further investigation, since discrepancies may lead to biased conclusions and, consequently, impact clinical and/or regulatory decisions.

Ophthalmic Res. 2018;60(2):55-68. doi: 10.1159/000489932.

2018
https://www.ncbi.nlm.nih.gov/pubmed/29975961

Drug-induced hypersensitivity: a 5-year retrospective study in a hospital electronic health records database

Drug-induced hypersensitivity: a 5-year retrospective study in a hospital electronic health records database

Drug-induced hypersensitivity: a 5-year retrospective study in a hospital electronic health records database

Mendes D, Alves C, Loureiro M, Fonte A, Batel Marques F

Journal of Clinical Pharmacy and Therapeutics

2018

Quantification of Retinal Microvascular Density in Optical Coherence Tomography Angiography Images in Diabetic Retinopathy.

Quantification of Retinal Microvascular Density in Optical Coherence Tomography Angiography Images in Diabetic Retinopathy.

Quantification of Retinal Microvascular Density in Optical Coherence Tomography Angiography Images in Diabetic Retinopathy.

Durbin MK, An L, Shemonski DS, Soares M, Santos T, Lopes M, Neves C, Cunha-Vaz J.

JAMA Ophthalmol. 2017;135(4):370-376.

2017